CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset
By FormBlends Medical Team · Last updated: April 25, 2026
VK2735 is ahead. CT-388 is still more of a watchlist asset than a category-defining one. That can change, but today this is mainly a comparison between a late-stage contender and a promising chaser.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. VK2735 is Phase 3, while CT-388 is Phase 2. CT-388 is usually a better fit for readers tracking roche's chance to become more relevant in obesity from a mid-stage position, while VK2735 is usually a better fit for readers who care more about which mid-cap obesity story is already closest to the real league table. Cost also matters: CT-388 is listed at Trial-stage asset; pricing unknown, while VK2735 is listed at Trial-stage asset; launch pricing unknown. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
PubMed evidence trail
Research sources used to frame this page
For CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
Compare available products and select the relevant treatment page for its specific next step.
Head-to-Head Comparison
CT-388
Pipeline Compound
Strengths
- Backed by Roche, which gives it serious scale if it works
- GLP-1/GIP profile keeps it in a proven mechanism class
- Still early enough to surprise if development accelerates
Weaknesses
- Phase 2 status leaves more room for failure
- Still behind VK2735 in visibility and maturity
Best For
Readers tracking Roche's chance to become more relevant in obesity from a mid-stage position.
Typical Cost
Trial-stage asset; pricing unknown
VK2735
Pipeline Compound
Strengths
- Phase 3 and already treated as one of the most important independent obesity assets
- Cleaner current momentum and greater investor familiarity
- More advanced path toward real-world commercialization
Weaknesses
- Competition is intense in the same mechanism lane
- Execution risk rises as the asset gets closer to the market
Best For
Readers who care more about which mid-cap obesity story is already closest to the real league table.
Typical Cost
Trial-stage asset; launch pricing unknown
Key Differences
- 1VK2735 is Phase 3, while CT-388 is Phase 2
- 2Both are GLP-1/GIP programs, so the major difference is maturity and sponsor context
- 3Roche brings scale to CT-388, but Viking currently has the clearer obesity-market momentum
- 4VK2735 is judged on near-term conversion; CT-388 is judged on whether it can catch up
Frequently Asked Questions
What is the difference between CT-388 and VK2735?
VK2735 is Phase 3, while CT-388 is Phase 2. Both are GLP-1/GIP programs, so the major difference is maturity and sponsor context.
Which is more effective, CT-388 or VK2735?
VK2735 is ahead. CT-388 is still more of a watchlist asset than a category-defining one. That can change, but today this is mainly a comparison between a late-stage contender and a promising chaser.
How much does CT-388 cost compared to VK2735?
CT-388 typically costs Trial-stage asset; pricing unknown, while VK2735 typically costs Trial-stage asset; launch pricing unknown.
Who should choose CT-388 over VK2735?
CT-388 is best for: Readers tracking Roche's chance to become more relevant in obesity from a mid-stage position.. VK2735 is best for: Readers who care more about which mid-cap obesity story is already closest to the real league table..
Ready to get started?
Connect with a licensed provider who can help you decide between CT-388 and VK2735 based on your goals, health history, and budget.